


of a known active substance having antitumor effect selected from the group consisting of pyrimidine derivatives or, optionally, a pharmaceutically acceptable acid addition salt thereof [] and an effective amount of a hydroximic acid derivative of the formula I

PS
7/13



wherein

R^1 represents a hydrogen atom or a C_{1-5} alkyl group,

R^2 stands for a hydrogen atom, a C_{1-5} alkyl group, a C_{3-8} cycloalkyl group or a phenyl group optionally substituted by a hydroxy or a phenyl group, or


R^1 and R^2 together with the nitrogen atom they are attached to form a 5 to 8 membered ring optionally containing one or more further nitrogen, oxygen or sulfur atom(s) and said ring can be condensed with another alicyclic or heterocyclic ring, preferably a benzene, naphthalene, quinoline, isoquinoline, pyridine or pyrazoline ring, furthermore optionally the nitrogen and/or sulfur heteroatom(s) are present in the form of an oxide or dioxide,

R^3 means a hydrogen atom, a phenyl group, a naphthyl group or a pyridyl group wherein said groups can be substituted by one or more halo atom(s) or C_{1-4} alkoxy group(s),

Y is a hydrogen atom, a hydroxy group, a C₁₋₂₄ alkoxy group optionally substituted by an amino group, a C₂₋₂₄ polyalkenyloxy group containing 1 to 6 double bond(s), a C₁₋₂₅ alkanoyl group, a C₃₋₉ alkenoyl group or a group of the formula R⁷-COO- wherein R⁷ represents a C₂₋₃₀ polyalkenyl group containing 1 to 6 double bond(s),

X stands for a halo atom, an amino group, a C₁₋₄ alkoxy group or X forms with B an oxygen atom, or

X and Y together with the carbon atom they are attached to and the -NR-O-CH₂- group being between said carbon atoms form a ring of the formula a




wherein

Z represents an oxygen atom or a nitrogen atom,

R stands for a hydrogen atom or

R forms with B a chemical bond,

A is a C₁₋₄ alkylene group or a chemical bond or a group of the formula b



wherein

R⁴ represents a hydrogen atom, a C₁₋₅ alkyl group, a C₃₋₈ cycloalkyl group or a phenyl group optionally substituted by a halo atom, a C₁₋₄ alkoxy group or a C₁₋₅ alkyl group,

R⁵ stands for a hydrogen atom, a C₁₋₄ alkyl group or a phenyl group,

m has a value of 0, 1 or 2,

n has a value of 0, 1 or 2,

or a pharmaceutically acceptable acid addition salt thereof in admixture with one or more conventional carrier(s),

wherein the antitumor activity is against tumors sensitive to the combination.

2. (Amended) A pharmaceutical composition as claimed in claim 1, comprising O-(3-piperidino-2-hydroxy-1-propyl)nicotinic amidoxime or a pharmaceutically acceptable acid addition salt thereof as the hydroximic acid derivative of the formula I.

6. (Amended) A method for reducing the side effect(s) in a patient requiring a treatment for a tumor comprising administering an effective amount of a known active substance having antitumor effect selected from the group consisting of pyrimidine derivatives or, optionally, a pharmaceutically acceptable acid addition salt thereof and an effective non-toxic amount of a hydroximic acid derivative of the formula I, wherein R¹, R², R³, A, X, B, R and Y are as defined in Claim 1, or a pharmaceutically acceptable acid addition salt thereof to the patient, and wherein said tumor is sensitive to said active substance; and the administration of the hydroximic acid derivative or a pharmaceutically acceptable acid addition salt thereof reduces the side effects experienced by the patient requiring treatment for a tumor.

7. (Amended) A method as claimed in claim 6, wherein said active substance is fluorouracil or a pharmaceutically acceptable salt thereof, and said hydroximic acid derivative is O-(3-piperidino-2-hydroxy-1-propyl)-nicotinic amidoxime or a pharmaceutically acceptable acid addition salt thereof.

10. (Amended) A method as claimed in claim 6, wherein said

AB hydroximic acid derivative is O-(3-piperidino-2-hydroxy-1-propyl)-

A3
nicotinic amidoxime or a pharmaceutically acceptable acid addition salt thereof.

A4
Please add the following claims:

11. A pharmaceutical composition as claimed in claim 1, comprising floxuridine or a pharmaceutically acceptable acid addition salt thereof as the active substance having antitumor activity.

12. A pharmaceutical composition as claimed in claim 1, comprising idoxuridine or a pharmaceutically acceptable acid addition salt thereof as the active substance having antitumor activity.

13. A pharmaceutical composition as claimed in claim 1, comprising doxifluoridine or a pharmaceutically acceptable acid addition salt thereof as the active substance having antitumor activity.

R3
7/03

14. A pharmaceutical composition as claimed in claim 1, comprising cytarabine or a pharmaceutically acceptable acid addition salt thereof as the active substance having antitumor activity.

15. A pharmaceutical composition as claimed in claim 1, comprising gemcitabine or a pharmaceutically acceptable acid addition salt thereof as the active substance having antitumor activity.

16. A pharmaceutical composition as claimed in claim 1, comprising ancitabine or a pharmaceutically acceptable acid addition salt thereof as the active substance having antitumor activity.

17. A pharmaceutical composition as claimed in claim 1, comprising carmofur or a pharmaceutically acceptable acid addition salt thereof as the active substance having antitumor activity.

18. A pharmaceutical composition as claimed in claim 1, comprising tegafur or a pharmaceutically acceptable acid addition salt thereof as the active substance having antitumor activity.

19. A pharmaceutical composition having antitumor activity with reduced side effect(s) comprising an enhanced effective amount of fluorouracil or a pharmaceutically acceptable acid addition salt thereof and O-(3-piperidino-2-hydroxy-1-propyl)nicotinic amidoxime

AP4 or a pharmaceutically acceptable acid addition salt thereof,
wherein said antitumor activity is against tumors sensitive to said
composition.

Attached hereto is a marked-up version of the changes made to
the application by this Amendment.